Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer
SPARC1613 is chemotherapeutic agent with a wide spectrum of anti-tumor activity. It is used extensively in the treatment of advanced carcinomas of the breast, ovaries, lung, and other solid tumors.This is pharmacokinetic study of SPARC1613 and Reference1613.
Recurrent or Metastatic Breast Cancer
DRUG: SPARC1613|DRUG: Reference1613
Maximum observed concentration (Cmax), Pre-dose,post dose upto 3 days
Adverse events, Adverse events encountered following dosing with SPARC1613 and Reference1613 will be recorded as per CTCAE4.03, First dose of trial drug to one month after last dose.
The purpose of this study is to evaluate level of test medication with respect to time in the body, and safety when compared with the reference medication Subject will be randomly assigned to receive an intravenous infusion of either SPARC1613 delivered over 25 (±1) minutes or Reference1613 delivered over 30 (±1) minutes